A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All...
Sparad:
Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Materialtyp: | Artigo |
Språk: | engelska |
Publicerad: |
2024
|
Länkar: | https://doi.org/10.1038/s41467-024-51315-8 https://www.nature.com/articles/s41467-024-51315-8.pdf |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|